|
Bio Expo Online
Biotech CollaborationsMorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease - Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies
MUNICH, GERMANY — (Marketwire) — 11/26/08 — MorphoSys AG (FSE: MOR; Prime StandardSegment, TecDAX) and Galapagos NV (Euronext: GLPG) announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel [...]
Fragment Based Screening Service at CRELUX and ZoBio - Munich (D) and Leiden (NL), November 24, 2008 / b3c newswire / – CRELUX and ZoBio announced today that they have successfully executed their first fragment based screening projects from a jointly established platform.
One of the first targets, which also will be made accessible to customers, was Pim1, a kinase that has been implicated in [...]
Company and People Notes: Patheon and Solvias Form Alliance; AstraZeneca Appoints Rich Fante President of US Business; More… - Nov 20, 2008
ePT–the Electronic Newsletter of Pharmaceutical Technology
Company Notes
San Jose, CA (Nov. 14)—AnaSpec established a new facility dedicated to peptide production that complies with good manufacturing practice (GMP). The new facility is adjacent to AnaSpec’s headquarters and provides 5000 ft2 of dedicated GMP space, including two Class 10,000 cleanrooms. AnaSpec produces GMP [...]
Galapagos and Merck Serono Enter New Collaboration Agreements - Mechelen, Belgium; 18 November 2008 – Galapagos NV (Euronext: GLPG) announced today new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is €1.1 million over one year.
Galapagos’ service division BioFocus DPI will provide SoftFocus© compounds for use in Merck Serono’s drug discovery [...]
Applied Biosystems and Asuragen Collaborate with the Critical Path Institute to Improve Drug Toxicity Screening - FOSTER CITY, Calif., Nov 06, 2008 (BUSINESS WIRE) — Drug toxicity accounts for billions of lost dollars to the pharmaceutical industry each year and is a leading cause of pre-clinical drug failures. The U.S. Food and Drug Administration (FDA) and other [...]
WuXi PharmaTech Inks New Three-year Deal with Pfizer - WuXi PharmaTech (NYSE: WX) has signed a new three-year CRO deal with Pfizer (NYSE: PFE) to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also provides Pfizer with synthetic chemistry, parallel [...]
The German Cancer Research Center Investigates the Role of miRNAs in Carcinogenesis Using febit’s Geniom RT Analyzer - LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, Oct. 20, 2008 - The German Cancer
Research Center, also known as DKFZ, in Heidelberg (Germany) chose febit´s newly
introduced Geniom® RT Analyzer to investigate the association of microRNAs (miRNAs)
and cancer.
miRNAs are small pieces of RNA with a maximum length of 23 nucleotides, which have
become an important focus of life-science research [...]
Hydra Biosciences Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team - CAMBRIDGE, Mass., Oct 24, 2008 (BUSINESS WIRE) — Hydra Biosciences, a privately held biopharmaceutical company focused on developing novel drugs using its expertise in Transient Receptor Potential (TRP) ion channels, announced today the expansion of its executive management team with the appointments of David Kimball, Ph.D. as Chief Scientific Officer and Christine Bellon, Ph.D. as [...]
BNC Collaborators Author High-profile Paper in Nature Nanotechnology - London, UK – 17 October 2008: Research by scientists collaborating with specialist product development consultancy, Bio Nano Consulting (BNC), into the workings of vancomycin - one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA - has been published in Nature Nanotechnology (October 2008). The researchers, led by [...]
TimTec and Collaborative Drug Discovery Team Up to Provide Chemically Searchable Natural Products and Derivatives Available to the Scientific Community - TimTec LLC., the international distributor of synthetic organic and natural compounds, and Collaborative Drug Discovery, Inc. (CDD), the community based research information management enterprise, announced today that the CDD web-based software now hosts TimTec’s Natural Product Library and Natural Derivatives Library. The TimTec natural product and derivative compounds are now available as a structure searchable [...]
CLC bio Signs Strategic Collaborative Agreement with J. Craig Venter Institute - Cambridge, Massachusetts, USA — October 9, 2008 — CLC bio, a world leading full-service bioinformatics solution provider announced today an agreement with the J. Craig Venter Institute, a not-for profit genomic-focused research institute. The accord consists of a multi-year site license for the entire CLC bio bioinformatics suite of products. The goal is to implement [...]
CLC bio Partners with Illumina to Provide Next Generation Sequencing Analysis Technology - Aarhus, Denmark — October 2, 2008 — Following an overwhelming reception of CLC Genomics Workbench 1.0, CLC bio is happy to announce the release of its next major version of their flagship product: CLC Genomics Workbench 2.0. Additionally, CLC bio has taken another important step in leading next generation sequencing data analysis by becoming an [...]
Sanofi-aventis signs a collaboration agreement with RainDance Technologies and Louis Pasteur Univers - The FINANCIAL — Sanofi-aventis announced on September 26 the launch of the dScreen Consortium, a research initiative conducted with RainDance Technologies, Inc., Lexington, Massachusetts, and Louis Pasteur University, Strasbourg, France, to develop the next generation of High-Throughput Screening (HTS) for drug discovery applications.
The consortium was founded with the assistance of the Alsace BioValleyTM Cluster, France, which helped [...]
First of 100 Arab Human Genomes Sequenced by Saudi Biosciences, Beijing Genomics Institute Shenzhen, and CLC bio - Riyadh, Kingdom of Saudi Arabia — September 9, 2008 — An international consortium consisting of Saudi Biosciences, Beijing Genomics Institute Shenzhen, and CLC bio have in a joint effort performed an initial sequencing and analysis of the first Arab human genome, as part of a large project to sequence 100 Arab [...]
TOCRIS SIGNS EXCLUSIVE DEAL TO SUPPLY GEFITINIB - September 4th, 2008 - Tocris Bioscience announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product [...]
AstraZeneca, Singapore institutions sign innovative new partnership to develop anti-cancer compounds - Healthcare company AstraZeneca Plc (AZN: News, Chart, Quote ,AZN.L: News, Chart, Quote ) said Friday that it signed an innovative new partnership with the National Cancer Centre Singapore, or NCCS, and the National University Hospital, or NUH, for development of anti-cancer compounds. The [...]
Pharma Invests Big in Stem Cells - GSK gives the Harvard Stem Cell Institute $25 million.
Today, the pharma company GlaxoSmithKline (GSK) announced a five-year, $25-million-plus collaborative agreement with the Harvard Stem Cell Institute to develop new methods for screening drugs with stem cells.
“GSK believes stem cell science has great potential to aid the discovery of new medicines by improving the screening, identification, [...]
Seegene and Shimadzu Agree to Join Multi-Pathogen Tests and Platform for Combined Analytics Solution - ROCKVILLE, MD and KYOTO, JAPAN–July 28, 2008 - Seegene, Inc. and Shimadzu Corporation today announced a strategic partnership to combine Seegene’s Seeplex(R) multi-pathogen tests with Shimadzu’s MultiNA (1) analytical platform. Under terms of the deal, Shimadzu and Seegene will collaborate on integrating the Seeplex polymerase chain reaction-based tests with Shimadzu’s [...]
Seegene/Lab901 brings a New Detection Platform for Multiple Pathogens to European Hospitals - Rockville, MD, and Edinburgh, Scotland, June 17, 2008: Seegene and Lab901 today announced the availability of a novel automated multi-pathogen walk-away detection platform for European hospitals. Based on the Seeplex(R) multiplexing PCR system and ScreenTape(R) gel electrophoresis detection system, this new Seeplex/ScreenTape detection platform will be introduced to clinical and [...]
Beijing Genomics Institute signs global site license with CLC bio for Next Generation Sequencing software platform - Aarhus Denmark, July 3rd, 2008 – Beijing Genomics Institute (BGI) has signed a global site license agreement for CLC bio’s Next Generation Sequencing solution, CLC Genomics Workbench. The site license covers all researchers at all BGI sites, both inside and outside of China.
Head of Bioinformatics Division at BGI, Ruiqiang Li states, “We [...]
|
|
|
